What top creators are saying about Eli Lilly and Company(LLY)— Page 3

Potential future partnership with HIMS for retatrutide; HIMS has avoided competing with Lilly's tirzepatide.

Mentioned as a 'usual suspect' in political campaign contributions seeking to maintain Washington influence.

Holds a significant investment moat through patent protection on pharmaceutical chemistry; Retatrutide represents a high-potential next-generation metabolic treatment.

Identified as a primary tradable asset to capture the massive growth in the peptide and weight-loss market.

Collaborating with NVIDIA to utilize AI for drug discovery and R&D pipeline acceleration.

Viewed as brilliant for bypassing Pharmacy Benefit Managers (PBMs) to sell GLP-1 drugs directly to patients.

Positioned as a regulated heavyweight in the biopharmaceutical space with high-demand products like Retatrutide in trials.

Beneficiary of the 'Performance Medicine' trend among high-performers, specifically with its Retatrutide product.

Experiencing a massive revenue boom from next-generation peptides like Terzepatide and the upcoming Retatrutide catalyst.

Faces significant policy risk from federal and state-level price caps on insulin and potential competition from imported drugs.

Viewed as a more transformative investment than AI with significant upside due to health and addiction applications.

Remains a primary mover in the obesity drug market with Retatrutide showing subjects losing up to one-third of body weight in Phase 3 trials.

GLP-1 drugs are viewed as a more transformative economic force than AI, with massive potential to reduce healthcare costs.

Viewed as a potential 'Magnificent 7' member due to leadership in longevity and GLP-1 medications.

Developing Retatrutide, a potential 'game changer' drug that could disrupt the current Semaglutide market.

While facing pricing pressure, the company is actively onshoring manufacturing with six new plants in the U.S.

The normalization of weight loss drugs for non-diabetic use signals a strong bullish trend for the dominant market leaders.

Extremely optimistic view based on its pipeline drug retatrutide, described as a potential 'miracle drug' and 'blockbuster' that could be superior to current GLP-1s.

AI is expected to create massive opportunities in healthcare for companies like Eli Lilly, particularly for services like 'Lilly Direct'. However, significant regulatory hurdles in Western countries are a key risk that could slow down monetization.

Significant advertising spend on the new drug EpGliss suggests high expectations as a future revenue driver. The launch and market reception are critical indicators of the company's growth pipeline and future earnings potential.

The speaker's bearish view on GLP-1 drugs, due to their perceived negative impact on human drive, poses a long-term, non-financial risk to the company as part of the broader sector.

HIMS made a very smart strategic decision to never offer compounded versions of Lilly's drug, which is seen as a key advantage and de-risking factor, as it avoids conflict with the 'jewel of healthcare in America'.

At the forefront of the lucrative weight-loss drug market. Its drug, retatrutide, was singled out as a potential trillion-dollar drug. Potential new regulations restricting competition would be a massive bullish event.

The discussion of GLP-1 drugs' measurable public health impact signals a large and growing market, which could be a long-term tailwind for the pharmaceutical companies that dominate this space, such as Eli Lilly.

The speaker is very bullish, predicting the weight loss market will 'likely belong to Lilly towards year-end 2026' due to its superior product pipeline, particularly its upcoming drug Ritatrudide.

Mentioned as a 'Big Pharma' company defending its drug patents against compounding pharmacies like Hims. Its drug pipeline, including future drug retatrutide, could make current legal battles obsolete.

The speaker is extremely bullish, predicting LLY will 'own the entire market' for weight-loss drugs by late 2026 with its next-generation drug, retatrutide, making it a better long-term investment than NVO.

Considered to be 'winning the weight loss drug wars' after reporting earnings and revenue that crushed expectations and guiding for 25% revenue growth.

The company can 'tweak these medicines' (GLP-1s) to create new versions targeting specific conditions beyond weight loss, such as cardiovascular health, massively expanding the potential market. It is a key player to watch in a 'game-changing' technology sector.

The company is described as 'growing very meaningfully' and gaining strength, with its stock up 10% after earnings. It is seen as having a competitive advantage over its main rival.

Bullish outlook, positioned as a strong, long-term leader and innovator in the weight-loss drug market. Its future pipeline, including the drug Retatrutide, is seen as a significant catalyst.

Viewed as the clear winner in the GLP-1 market, with revenue up 43%, a raised 2026 revenue guidance to $80 billion, and confidence it will dominate the market.

Highlighted for its strong earnings and an 8% gain on a red market day. Part of a resilient sector using AI to bring drugs to market 'much more rapidly and much more cheaply,' which should help it 'outperform'.

The stock was up 7-8% after 'crushing' earnings, with revenue up 43% year-over-year, demonstrating exceptional strength and positioning it as a potential safe haven.

The massive growth runway for GLP-1 drugs is considered a major tailwind for leading pharmaceutical companies in the space, including Eli Lilly.

The dramatic price reduction and inclusion of its GLP-1 drugs in Medicare/Medicaid plans could massively expand the addressable market, and its innovation pipeline with drugs like Retatrutide indicates a potential for maintaining a competitive advantage.

Has significant exposure to the psychiatric drug market through Prozac and Zyprexa, but faces potential reputational and legal risks due to detailed negative patient experiences with these specific drugs, particularly Zyprexa.

Its partnership with NVIDIA is cited as an example of a positive trend: applying AI to optimize clinical trials and make the drug development process more efficient.

The GLP-1 drug theme represents a major growth driver for pharmaceutical companies in the space, including Eli Lilly (LLY), which makes similar drugs, reinforcing the idea that this is a long-term, transformative trend in healthcare.

Cited as a prime example of a potential acquisition target for Big Tech in a speculative, long-term M&A trend involving AI and pharma.

While the market for GLP-1 drugs is enormous, the potential for government-enforced price cuts in the US represents a significant risk to profitability.

Faces a significant risk from the anticipated market entry of over 10 cheaper, Chinese-made GLP-1 drugs, which will likely lead to a major price war and erode market share.

Partnering with NVIDIA to use cutting-edge AI for drug discovery, which could accelerate R&D and solidify its leadership position in the highly profitable pharma market.

Partnering with Nvidia in a $1 billion deal to create an AI drug discovery lab, which positions the company at the forefront of using advanced technology for pharmaceutical innovation.

Investing in an AI partnership with NVIDIA could dramatically shorten drug discovery timelines, reduce R&D costs, and increase the success rate of new medicines, giving the company a significant competitive advantage.

The company has significant leverage and pricing power due to its highly sought-after products (like Zetbound), allowing it to bypass the restrictive PBM system and control its distribution.

Partnering with NVIDIA to use AI to transform drug discovery, which is a significant positive development.

A small amount is held as a 'trade' rather than a long-term investment. Sentiment is neutral due to a lack of deep industry understanding and a noted risk of competition from 'gray market Chinese peptides'.

Experiencing significant revenue growth as a leader in the massive and rapidly expanding GLP-1 drug market, though investors should consider long-term risks like competition and side effects.

Mentioned as a potential acquirer in the pharma space, but the analysis prefers owning acquisition targets (biotech) rather than the large-cap acquirers.